What are the fundraising trends in the healthcare AI market?
In our healthcare AI market deck, you will find everything you need to understand the market
SUMMARY
We analyzed publicly disclosed equity rounds raised by pure-play Healthcare AI companies between January 2024 and May 2026, using a $300K minimum disclosed round size, an equity-only filter, and a pure-play threshold requiring more than 80% of activity to sit inside Healthcare AI. The resulting sample covers 29 qualifying rounds in 2024, 43 in 2025, and 34 in year-to-date 2026.
The Healthcare AI market expanded sharply from 2024 to 2025. Total identified funding rose from about $2.75B to about $4.55B, while deal count increased from 29 to 43, which means the market grew in both dollars and activity.
The 2026 year-to-date picture is more nuanced. Healthcare AI funding reached about $1.45B across 34 deals through May 2026, below the comparable 2025 capital total but far above the comparable 2025 deal count.
The practical interpretation is that 2025 was a mega-round year and 2026 is a breadth year. The Healthcare AI market is seeing more companies raise, but fewer extraordinary platform rounds are inflating the totals.
Round sizes confirm the shift. The median round fell from about $51M in the comparable 2025 period to about $21M in year-to-date 2026, while the average round fell much more sharply because the 2025 comparison included several very large financings.
Capital is moving toward more proven companies. In year-to-date 2026, Series B and later rounds captured about 62% of capital, while first financings represented only about 10% of dollars.
Care Workflow AI is the broadest current category, with 12 of 34 year-to-date 2026 deals. But Clinical AI Tools, Life Science AI, Revenue Cycle AI, Diagnostic AI Software, and Payer AI Platforms all show meaningful capital activity, making the 2026 mix less dependent on a single category than 2024 or 2025.
North America remains the center of gravity. It accounted for about 88% of year-to-date 2026 deals and 82% of capital, while Europe, Asia-Pacific, and the Middle East each contributed narrower but still visible signals.
The investor base remains broad. Year-to-date 2026 includes roughly 83 disclosed investors and 37 tier-1 investors, with repeat activity from General Catalyst, Insight Partners, Transformation Capital, Y Combinator, and Lightspeed Venture Partners.
The main conclusion is that the Healthcare AI market has moved past novelty funding. Investors are still backing AI in healthcare, but the strongest rounds increasingly attach to budget owners, clinical trust, workflow ROI, regulatory credibility, payer savings, or life-science leverage.
This chart, featured in our healthcare AI market deck, illustrates how revenue is distributed across customer segments in the healthcare AI market
Is more or less capital going into the Healthcare AI market?
More capital is going into the Healthcare AI market structurally, but less capital has gone into the Healthcare AI market so far in 2026 than over the comparable early-2025 period. The best reading is therefore mixed: the full-year comparison shows expansion from 2024 to 2025, while the latest 2026 signal shows lower dollars but much higher deal activity.
The full-year comparison is strong. Identified Healthcare AI funding rose from about $2.75B in 2024 to about $4.55B in 2025, an increase of roughly 65%, while deal count rose from 29 deals to 43 deals.
The freshest comparison is softer on dollars. From January through May 2026, the Healthcare AI market raised about $1.45B across 34 deals, compared with about $2.15B across only 10 deals over the same calendar window in 2025.
That does not mean the Healthcare AI market collapsed. The comparable 2025 period was distorted by very large financings, including OpenEvidence, Isomorphic Labs, Abridge, and Lila Sciences, so the current-year decline is partly a normalization after an unusually capital-heavy start to 2025.
The real signal is that capital is still flowing, but its shape has changed. The Healthcare AI market is moving from a few spectacular validation rounds toward a broader set of commercialization rounds across clinical AI, workflow AI, payer AI, revenue-cycle AI, diagnostic AI, and life-science AI.
Is Healthcare AI funding driven by more deals or larger rounds?
Healthcare AI funding in 2026 is being driven more by deal count than by larger rounds. The Healthcare AI market produced 34 qualifying deals through May 2026, compared with only 10 deals over the same period in 2025, even though total capital was lower.
That contrast matters because it separates market activity from market inflation. If larger rounds were driving the 2026 market, average and median deal sizes would be rising. Instead, the average round is about $43M and the median round is about $21M, both far below the comparable 2025 period.
The full-year 2025 versus 2024 comparison tells a related story. Total capital rose from about $2.75B to about $4.55B, and deal count rose from 29 to 43, but the median round fell from $50M to $30M. That means the Healthcare AI market expanded, but the typical company did not necessarily raise more money.
The strongest interpretation is that 2025 was a mega-round year, while 2026 so far is a breadth year. The Healthcare AI market is not cooling in entrepreneurial activity; it is cooling in giant-check concentration.
For deeper benchmarks on Healthcare AI deal sizes, median rounds, and concentration patterns, see the full Healthcare AI market report.
Is Healthcare AI capital moving toward later-stage or earlier-stage companies?
Healthcare AI capital is moving back toward later-stage companies so far in 2026, even though Series A remains the most common stage by deal count. Series B and later rounds captured about 62% of year-to-date 2026 capital, while Seed and Series A captured about 38%.
This is a reversal from the comparable early-2025 period. Early-stage and unknown-stage platform financings captured about 86% of capital then, largely because Isomorphic Labs, Lila Sciences, and OpenEvidence created unusually large early or formation-stage rounds.
The 2026 stage mix looks more mature. OpenEvidence raised $250M at later stage, Aidoc raised $150M at Series D+, Qualified Health raised $125M at Series B, Nitra counted $90M of equity, Heidi raised $65M at Series B, and Alaffia raised $55M at Series B.
The practical takeaway is that the Healthcare AI market is no longer mainly rewarding the promise of new AI-native formation. It is increasingly rewarding evidence of adoption, distribution, enterprise deployment, payer ROI, regulatory credibility, or clinical trust.
This chart, featured in our healthcare AI market deck, compares the main business model options for ambient AI companies
Is the Healthcare AI market maturing or still experimental?
The Healthcare AI market is maturing, although parts of it remain experimental. The clearest maturity signal is that the market has shifted from very large platform-formation rounds in 2024 and 2025 toward a larger number of more commercially specific rounds in 2026.
Several indicators point in that direction. First financings represent only 6 of 34 deals in year-to-date 2026, or about 18% of deal count, and only about 10% of capital. In a highly experimental market, first financings and seed rounds would usually carry more of the activity.
The stage mix also supports a maturity reading. Series B and later rounds captured about 62% of capital, while seed rounds captured only about 2%. The largest checks went to companies that can plausibly claim institutional trust or commercial validation.
Still, the Healthcare AI market is not mature in the way a conventional software market is mature. Care Workflow AI has the most deals but a median round of only about $18M, which suggests many workflow wedges are still being tested by separate startups.
The strongest conclusion is that the Healthcare AI market has moved beyond pure novelty. Investors are no longer funding “AI for healthcare” as a generic theme; they are funding specific bottlenecks such as claims waste, clinical search, documentation burden, medication access, radiology triage, post-discharge care, revenue leakage, and drug design.
Are new startups still entering the Healthcare AI market?
Yes, new startups are still entering the Healthcare AI market, but new-company formation is no longer the main driver of capital. In year-to-date 2026, first financings represent 6 of 34 deals, or about 18% of activity, but only about $139M of the $1.45B raised.
That is a meaningful signal. New companies such as Neuropacs, Ease Health, Procode AI, Latent, Worki, and Almanac Health are still getting funded, but most dollars are going to companies that had already raised before.
The comparison with 2025 is instructive. In full-year 2025, first financings represented about 14% of deals and 19% of capital. Over the comparable early-2025 period, first financings represented 20% of deals and 37% of capital, largely because Isomorphic Labs and Lila Sciences were large platform-formation events.
The Healthcare AI market is therefore not closed to new entrants, but the bar has risen. New startups need a sharper wedge than “AI improves healthcare,” and the funded 2026 entrants tend to attack concrete problems such as behavioral-health operations, medication access, workforce infrastructure, revenue-cycle automation, evidence support, or neurological diagnostics.
For a broader view of new entrants, first financings, and category formation, see the Healthcare AI market deck.
Are more investors entering the Healthcare AI market?
Yes, more investors are entering the Healthcare AI market in the sense that the disclosed investor base remains broad and the current-year pace is strong. By May 2026, the dataset had roughly 83 disclosed investors and 37 tier-1 investors across 34 deals.
That is a large number for an incomplete year. Full-year 2025 had about 106 disclosed investors across 43 deals, while full-year 2024 had roughly 90 to 100 disclosed investors across 29 deals.
The more important point is not just the number of investors, but the mix. The Healthcare AI market includes generalist venture firms, AI-platform investors, healthcare specialists, life-science backers, payer and provider strategics, and corporate venture arms.
The honest interpretation is that Healthcare AI is no longer a niche healthtech-only market. Generalist AI investors are participating, healthcare specialists remain active, and strategic investors matter where access, workflow integration, clinical validation, or payer economics are central to the thesis.
This chart, featured in our healthcare AI market deck, shows annual funding in healthcare AI startups
Are top investors getting more or less active in Healthcare AI?
Top investors are still active in Healthcare AI, but their activity is selective rather than uniformly concentrated. In year-to-date 2026, General Catalyst appears in 4 deals, while Insight Partners, Transformation Capital, Y Combinator, and Lightspeed Venture Partners each appear in 2 deals.
That is active, but it is not a market where one investor owns the entire map. The better reading is that leading investors are placing repeat bets across several bottlenecks rather than treating Healthcare AI as one monolithic sector.
The full-year comparison supports that view. In 2024, repeat investors included a16z with 5 deals, Lightspeed with 3, and several investors with 2. In 2025, General Catalyst had 4 deals, GV had 3, a16z had 3, Sequoia had 3 if normalized, and several others had 2.
The key shift is where top investors are placing repeat bets. In 2026, leading names show up across clinical AI, payer AI, revenue-cycle AI, diagnostic AI, care workflow, and life-science AI, which suggests they are sampling multiple healthcare bottlenecks rather than only backing ambient documentation or AI drug discovery.
Which Healthcare AI subcategories are gaining momentum?
Care Workflow AI, Revenue Cycle AI, Payer AI Platforms, and Diagnostic AI Software are gaining momentum in the Healthcare AI market so far in 2026, while Clinical AI Tools remains a major capital magnet. The clearest signal is that the current-year category mix is more balanced than in 2024 or 2025.
Care Workflow AI is the broadest momentum category. It has 12 of 34 year-to-date 2026 deals and about $413M of capital, spanning care management, workflow automation, behavioral-health operations, post-discharge care, medication access, clinical agents, workforce infrastructure, and AI scribes.
Revenue Cycle AI has a stronger 2026 signal than it had in 2025. It has 4 deals and about $161M in year-to-date 2026, including Nitra, Procode AI, Translucent, and Adonis. That matters because revenue leakage, denials, coding, payment operations, and finance visibility have clear budget owners.
Payer AI is also becoming more visible. It moved from one small 2024 deal to one large 2025 deal and then to 3 deals and $92M in year-to-date 2026, including Alaffia, Pasito, and Keebler Health.
Diagnostic AI Software looks quiet by deal count but powerful by proof threshold. Aidoc’s $150M round drove the category’s 2026 capital relevance, which confirms that diagnostic AI companies with regulatory credibility and deployment proof can still command large late-stage checks.
We cover this category shift in more detail in the deeper analysis of the Healthcare AI market.
Which Healthcare AI subcategories are losing momentum?
Life Science AI is losing relative momentum in the Healthcare AI market so far in 2026, and Care Workflow AI is losing capital intensity even while gaining deal breadth. This does not mean either category is weak; it means their funding profiles are less dominant than they were in 2024 or 2025.
Life Science AI is the clearest relative slowdown. In 2024, it captured about $1.75B, or 64% of all capital, driven by Xaira, Formation Bio, Enveda, Zephyr AI, Cradle, AQEMIA, and Atropos. In 2025, it still captured about $1.41B, or 31% of capital.
So far in 2026, Life Science AI has about $239M, or 17% of capital. That is still meaningful, but it is no longer the center of gravity because the category has not repeated the exceptional platform-formation rounds seen in 2024 and 2025.
Care Workflow AI is losing momentum only in the sense of capital intensity. It leads current-year deal count, but its median round is about $18M, which suggests an active but fragmented application layer rather than a category currently producing many Abridge- or Ambience-sized mega-rounds.
The weaker profile today is not any named subcategory by itself. The weaker profile is the undifferentiated AI workflow company that cannot show enterprise depth, proprietary distribution, workflow ownership, measurable ROI, or clinical trust.
This chart, featured in our healthcare AI market deck, looks at Tempus AI’s strategy in healthcare AI
Which regions are gaining momentum in Healthcare AI funding?
North America is gaining momentum by deal count, while the Middle East appears as an important current-year capital outlier because of Aidoc. The Healthcare AI market remains overwhelmingly North America-led.
So far in 2026, North America accounts for 30 of 34 deals, or about 88% of activity, and about $1.19B, or 82% of capital. Over the comparable early-2025 period, North America accounted for 7 of 10 deals and about 69% of capital.
The full-year view is stable. North America had 23 of 29 deals and about 89% of capital in 2024, then 35 of 43 deals and about 81% of capital in 2025. The U.S. healthcare system creates unusually large AI opportunities because administrative complexity, payer fragmentation, physician burden, and health-system financial stress are all acute and monetizable.
The Middle East gains current-year capital share because Aidoc’s $150M round is classified there. This is not broad regional momentum in the same sense as North America; it is one globally relevant diagnostic AI company driving a large regional capital signal.
Asia-Pacific also has a narrow but credible signal through Heidi Health’s $65M round. That shows APAC companies can break through, but the region has not yet produced broad Healthcare AI deal volume comparable to North America.
For ongoing regional tracking across North America, Europe, Asia-Pacific, and the Middle East, see the market report covering Healthcare AI geography.
Which regions are losing momentum in Healthcare AI funding?
Europe is losing momentum so far in 2026 relative to its unusually strong 2025 position. Europe still has Healthcare AI activity, but its current-year capital share is much lower than in 2025.
In full-year 2025, Europe captured about $793M, or 17% of Healthcare AI capital, from 5 deals. That figure was boosted heavily by Isomorphic Labs’ $600M financing and Biorce’s $52.5M round.
So far in 2026, Europe has only 2 deals and about $42M, or roughly 3% of capital. Tucuvi and nyra health are real and relevant companies, but they are not the same scale as Europe’s 2025 life-science platform financings.
The right interpretation is not that European Healthcare AI has become uninvestable. Europe’s 2025 number was unusually dependent on a few large life-science and clinical workflow financings, and without another Isomorphic-sized round, Europe’s capital share naturally falls.
Latin America and Africa remain absent in the identified funding activity across 2024, 2025, and year-to-date 2026. That absence reinforces that Healthcare AI funding is still not globally distributed across all regions.
Is Healthcare AI becoming more global or regionally concentrated?
The Healthcare AI market is becoming more regionally concentrated by deal count, even though a few global winners make the capital map look more international. So far in 2026, North America accounts for about 88% of deals and 82% of capital.
The freshest comparison reinforces the point. Over the comparable early-2025 period, North America had about 70% of deals and 69% of capital. In year-to-date 2026, both shares are higher.
The full-year comparison is more balanced but still concentrated. In 2024, North America captured about 89% of capital and 79% of deals. In 2025, North America captured about 81% of both capital and deals.
The best interpretation is that Healthcare AI is technically global but commercially regional. Talent, model development, and company formation can happen across regions, but venture-scale Healthcare AI funding still clusters around the U.S. commercialization environment.
Global winners can emerge, but they usually need proof that travels into U.S.-style enterprise healthcare demand. That means payer complexity, health-system budgets, revenue-cycle pain, clinical documentation burden, regulatory trust, or provider deployment can matter as much as model quality.
This chart, featured in our healthcare AI market deck, shows how EHR adoption has driven growth in the healthcare AI market over time
Is Healthcare AI capital moving toward proven winners or new opportunities?
Healthcare AI capital is moving toward proven winners, while a smaller amount of capital is still testing new opportunities. In year-to-date 2026, first financings are about 18% of deals but only about 10% of capital.
This is a major change from the earlier platform-formation pattern. In 2024, first financings were only about 3% of deals but captured 36% of capital because Xaira raised $1B as a first financing. In the comparable early-2025 period, first financings captured 37% of capital because Isomorphic Labs and Lila Sciences represented large new platform formations.
So far in 2026, the largest rounds are mostly follow-ons. OpenEvidence, Aidoc, Qualified Health, Nitra, Proxima, AcuityMD, Heidi Health, and Alaffia are not all late-stage public-market-ready companies, but they are mostly not brand-new experiments either.
The Healthcare AI market has entered a validation phase. Investors still fund new opportunities when the problem is sharp, but the larger checks now require evidence of adoption, enterprise workflow depth, payer ROI, clinical trust, regulatory credibility, health-system relevance, or a clear path to category leadership.
The full market view on Healthcare AI winners tracks which companies are attracting follow-on capital and which new entrants still need to prove they can raise again.
Is the Healthcare AI market becoming winner-takes-most?
The Healthcare AI market is not fully winner-takes-most, but it is clearly winner-takes-more. The evidence points to a barbelled market: a few companies capture very large rounds, while a long tail of smaller companies continues to raise modest financing.
Concentration has eased so far in 2026 compared with the most distorted periods. The top deal captured about 17% of year-to-date 2026 capital, compared with about 20% in full-year 2025 and about 36% in full-year 2024.
Still, the top 10 deals captured about 70% of current-year capital, while the bottom half of deals captured only about 14%. That is not an equal market. It is a market where many companies can raise, but a small set of companies captures the money that defines category leadership.
The Healthcare AI market is less winner-takes-all than foundation-model markets, but more winner-takes-more than traditional vertical SaaS. Trust, compliance, integration, proprietary feedback loops, health-system access, and payer distribution can compound once a company breaks through.
Is the next wave of Healthcare AI winners becoming visible?
The next wave of Healthcare AI winners is becoming visible, but the companies are being filtered by proof more than by novelty. The most visible 2026 candidates are companies that connect AI performance to measurable healthcare outcomes or budget lines.
The current-year leaders are not all in the same category. OpenEvidence sits in clinical decision support, Aidoc in diagnostic imaging, Qualified Health in enterprise health-system AI, Nitra and Adonis in revenue-cycle operations, Alaffia and Keebler in payer workflows, and Proxima, AcuityMD, and Fathom in life-science or medtech intelligence.
That spread matters because it shows the Healthcare AI market is not producing one single winner profile. The winners are likely to emerge separately across clinical trust, diagnostic validation, workflow ROI, revenue impact, payer savings, and life-science leverage.
The practical filter is simple. The next Healthcare AI winners will be companies that can name the buyer, show the workflow, prove the value, and survive the trust requirements of healthcare. Better models alone are not enough.
As this chart shows, and as featured in our healthcare AI market deck, search interest in healthcare AI has grown rapidly
Is the Healthcare AI funding landscape fragmenting or consolidating?
The Healthcare AI funding landscape is fragmenting by company count and consolidating by capital. Year-to-date 2026 has 34 deals across 34 companies, which shows a broad set of startups getting funded. But the top 10 deals still capture about 70% of capital.
This is the central tension in the Healthcare AI market. Many companies can raise money because healthcare contains many painful workflows, but only a smaller group can raise large checks because healthcare buyers are slow, regulated, integration-heavy, and trust-sensitive.
The 2025 comparison reinforces the same pattern. Full-year 2025 had 43 deals across 37 companies, but the top 10 deals captured about 72% of capital. That is fragmentation and consolidation at the same time.
The honest interpretation is that Healthcare AI is not consolidating in the sense that fewer companies exist. It is consolidating in the sense that the most credible companies are pulling away financially, especially when they can present themselves as platforms, operating systems, or control layers over important workflows.
Where is investor attention shifting in Healthcare AI?
Investor attention in Healthcare AI is shifting from giant early platform-formation bets toward commercially grounded workflow, clinical, payer, diagnostic, revenue-cycle, and life-science applications. The clearest 2026 signal is that capital is more evenly distributed across categories than in 2024 or 2025.
In 2024, Life Science AI captured about 64% of capital, largely because of Xaira’s $1B round and other large drug-discovery financings. In 2025, capital was split across Care Workflow AI, Life Science AI, and Clinical AI Tools, with OpenEvidence, Isomorphic Labs, Lila Sciences, Abridge, and Ambience defining the year.
So far in 2026, no single category dominates. Care Workflow AI has about 29% of capital, Clinical AI Tools about 27%, Life Science AI about 17%, Revenue Cycle AI about 11%, Diagnostic AI Software about 10%, and Payer AI Platforms about 6%.
That distribution says investor attention is broadening. The Healthcare AI market is no longer just about AI drug discovery or ambient clinical documentation; it now includes health-system enterprise AI, claims review, benefits operations, risk adjustment, revenue-cycle orchestration, diagnostic triage, behavioral health, medication access, clinical search, and medtech commercialization.
The direction of travel is toward measurable bottlenecks. The most fundable companies are not merely “AI-native”; they are attached to existing budget lines and painful failure points such as denied claims, physician search, documentation burden, radiology triage, care transitions, payer waste, medication delays, health-system financial risk, and drug-design timelines.
For real-time tracking of how investor attention is moving across Healthcare AI categories, see the Healthcare AI market report.
All the funding deals in the healthcare AI market from 2024 to Apr 2026
The table below lists every disclosed equity round in the supplied healthcare AI funding dataset between January 2024 and April 2026. It covers companies across care workflow AI, clinical AI tools, diagnostic AI software, life science AI, payer AI platforms, and revenue cycle AI.
Each row shows the company, the fundraising date, what the company does, its category, the funding stage, the round size, the region, whether it was a first financing or a follow-on, the tier-1 investor if any, and the announcement source. For the broader investability view, see our longevity market deck.
| Company | Date | What they do | Category | Stage | Deal size | Region | First/Follow-on | Tier 1 investor(s) | Source |
|---|---|---|---|---|---|---|---|---|---|
| Aidoc | Apr 2026 | Clinical AI medical-imaging platform for earlier diagnosis and triage. | Diagnostic AI Software | Series D+ | $150M | Middle East | Follow-on | Goldman Sachs Alternatives; General Catalyst; SoftBank Investment Advisors; NVentures | Axios |
| Fathom Therapeutics | Apr 2026 | Physics- and AI-enabled small-molecule drug design platform. | Life Science AI | Series A | $47M | North America | Follow-on | Sutter Hill Ventures; Alexandria Venture Investments | PR Newswire |
| LighthouseAI | Apr 2026 | AI and intelligence platform for pharmaceutical state licensing and compliance. | Life Science AI | Series A | $8M | North America | Follow-on | None identified | Access Newswire |
| Almanac Health | Apr 2026 | Research-validated clinical AI platform and evidence-based decision support. | Clinical AI Tools | Seed | $10M | North America | First financing | F-Prime; General Catalyst; Lightspeed Venture Partners | VCA Online |
| AcuityMD | Apr 2026 | AI platform for MedTech commercial intelligence and adoption. | Life Science AI | Series C | $80M | North America | Follow-on | Benchmark; Redpoint Ventures; ICONIQ | AcuityMD |
| Heidi Health | Apr 2026 | AI clinical scribe and healthcare AI agent platform. | Care Workflow AI | Series B | $65M | Asia-Pacific | Follow-on | Point72 Private Investments; Blackbird | Heidi Health |
| Worki | Apr 2026 | AI workforce infrastructure for healthcare operations. | Care Workflow AI | Seed | $2.75M | North America | First financing | None identified | PR Newswire |
| Keebler Health | Apr 2026 | LLM-native risk-adjustment platform processing unstructured clinical documentation. | Payer AI Platforms | Series A | $16M | North America | Follow-on | Flare Capital Partners; Sands Capital | Keebler Health |
| Latent | Apr 2026 | Clinical AI platform accelerating access to life-saving medications. | Care Workflow AI | Series A | $80M | North America | First financing | Spark Capital; Transformation Capital; General Catalyst; Y Combinator | Business Wire |
| Insight Health | Apr 2026 | Clinical-agent platform for healthcare administration. | Care Workflow AI | Series A | $11M | North America | Follow-on | Pear VC | Business Wire |
| Jimini Health | Mar 2026 | Clinician-supervised AI infrastructure for behavioral health. | Clinical AI Tools | Seed | $17M | North America | Follow-on | M13; Zetta Venture Partners | MedCity News |
| Avo | Mar 2026 | EHR-integrated clinical intelligence platform. | Clinical AI Tools | Series A | $10M | North America | Follow-on | None identified | Startup Health |
| Blossom Health | Mar 2026 | AI operating system for psychiatry. | Care Workflow AI | Series A | $20M | North America | Follow-on | None identified | PR Newswire |
| Qualified Health | Mar 2026 | Enterprise AI platform for health systems. | Care Workflow AI | Series B | $125M | North America | Follow-on | NEA | PR Newswire |
| Adonis | Mar 2026 | AI orchestration platform for healthcare revenue-cycle operations. | Revenue Cycle AI | Series C | $40M | North America | Follow-on | General Catalyst | PR Newswire |
| Doctronic | Mar 2026 | AI system for patient-facing medical care and prescription renewal. | Clinical AI Tools | Series B | $40M | North America | Follow-on | Lightspeed Venture Partners; Union Square Ventures | Business Wire |
| Dimer Health | Mar 2026 | Clinician-led AI-native transitional care medicine platform. | Care Workflow AI | Series A | $13.5M | North America | Follow-on | Team8 | PR Newswire |
| Condor Software | Mar 2026 | AI-powered financial intelligence platform for life sciences clinical, operational, and financial data. | Life Science AI | Series A | $24M | North America | Follow-on | Insight Partners | Insight Partners |
| Translucent | Mar 2026 | AI platform for health-system finance visibility and risk response. | Revenue Cycle AI | Series A | $27M | North America | Follow-on | GV; NEA | Business Wire |
| Amigo AI | Mar 2026 | Platform for building and training patient-facing clinical AI agents. | Clinical AI Tools | Series A | $11M | North America | Follow-on | Madrona; Optum Ventures | Business Wire |
| Nitra | Mar 2026 | AI-native operating platform for healthcare practices and back offices. | Revenue Cycle AI | Series B | $90M | North America | Follow-on | None identified | PR Newswire |
| Procode AI | Mar 2026 | AI-powered revenue-cycle-management company. | Revenue Cycle AI | Unknown | $4M | North America | First financing | None identified | FinSMEs |
| Ease Health | Feb 2026 | AI-native CRM, EHR, and RCM operating system for behavioral health providers. | Care Workflow AI | Series A | $41M | North America | First financing | Andreessen Horowitz | Business Wire |
| nyra health | Feb 2026 | AI neurorehabilitation software for speech, cognition, and motor therapy. | Clinical AI Tools | Series A | $21.6M | Europe | Follow-on | Wellington Partners | Vestbee |
| SECAI | Feb 2026 | Voice AI and clinical documentation automation for healthcare workflows. | Care Workflow AI | Series A | $6.2M | North America | Follow-on | None identified | AI-TechPark |
| Take2 | Feb 2026 | Autonomous AI agents for healthcare recruiting and workforce hiring. | Care Workflow AI | Series A | $14M | North America | Follow-on | Human Capital | PR Newswire |
| Lotus Health AI | Feb 2026 | AI-enabled doctor-visit model designed around insurance-free care access. | Clinical AI Tools | Series A | $35M | North America | Follow-on | None identified | HLTH |
| Synthpop | Feb 2026 | Agentic AI automation for provider, payer, and patient administrative workflows. | Care Workflow AI | Series A | $15M | North America | Follow-on | None identified | Business Wire |
| Pasito | Feb 2026 | AI-native workspace for group health, life, and retirement benefits operations. | Payer AI Platforms | Series A | $21M | North America | Follow-on | Insight Partners; Y Combinator | PR Newswire |
| Alaffia Health | Feb 2026 | Agentic AI for health-plan claims review and waste reduction. | Payer AI Platforms | Series B | $55M | North America | Follow-on | Transformation Capital; FirstMark Capital | TechStartups |
| OpenEvidence | Jan 2026 | AI medical search and clinical decision-support platform for physicians. | Clinical AI Tools | Series D+ | $250M | North America | Follow-on | Thrive Capital; DST Global | Business Wire |
| Neuropacs | Jan 2026 | AI-driven neurological diagnostics. | Diagnostic AI Software | Seed | $1M | North America | First financing | None identified | FinSMEs |
| Proxima | Jan 2026 | AI-enabled proximity-based medicines and drug discovery platform. | Life Science AI | Series A | $80M | North America | Follow-on | DCVC | Business Wire |
| Tucuvi | Jan 2026 | AI care-management voice platform for healthcare organizations. | Care Workflow AI | Series A | $20M | Europe | Follow-on | Cathay Innovation | Tucuvi |
| Iambic | Nov 2025 | AI-driven drug discovery and development platform. | Life Science AI | Growth Equity | $100M | North America | Follow-on | Sequoia | Iambic |
| Hippocratic AI | Nov 2025 | Clinically safe generative AI agents for healthcare workflows. | Care Workflow AI | Series C | $126M | North America | Follow-on | None counted | Business Wire |
| Honey Health | Oct 2025 | Back-office AI agents for healthcare organizations. | Care Workflow AI | Seed | $7.8M | North America | First financing | None counted | PR Newswire |
| Hyro | Oct 2025 | Responsible AI agent platform for healthcare. | Care Workflow AI | Growth Equity | $45M | North America | Follow-on | None counted | PR Newswire |
| OpenEvidence | Oct 2025 | AI medical search and clinical decision support. | Clinical AI Tools | Series C | $200M | North America | Follow-on | GV | Fierce Healthcare |
| ExaCare AI | Oct 2025 | AI agents for skilled nursing and home-care admissions and operations. | Care Workflow AI | Series A | $30M | North America | Follow-on | Insight Partners | PR Newswire |
| Counsel Health | Oct 2025 | Physician-supervised AI front door for healthcare. | Clinical AI Tools | Series A | $25M | North America | First financing | a16z; GV | Business Wire |
| DUOS | Oct 2025 | AI-powered digital health platform for member activation and benefits execution. | Payer AI Platforms | Growth Equity | $130M | North America | Follow-on | None counted | Business Wire |
| Attuned Intelligence | Oct 2025 | Supervised voice AI for hospital and health-system call centers. | Care Workflow AI | Seed | $13M | North America | First financing | None counted | PR Newswire |
| Assort Health | Oct 2025 | Voice AI platform for healthcare call centers. | Care Workflow AI | Series B | $76M | North America | Follow-on | Unknown | Fierce Healthcare |
| Lila Sciences | Oct 2025 | AI science platform extension round. | Life Science AI | Series A | $115M | North America | Follow-on | General Catalyst | Crunchbase |
| Heidi Health | Oct 2025 | AI medical scribe and clinical assistant. | Care Workflow AI | Series B | $65M | Asia-Pacific | Follow-on | None counted | Business Insider |
| Predoc | Sep 2025 | AI automation for medical-record retrieval and health-information management. | Care Workflow AI | Series A | $30M | North America | Follow-on | None counted | MobiHealthNews |
| Lila Sciences | Sep 2025 | Autonomous AI science platform for life sciences, chemistry, and materials science. | Life Science AI | Series A | $235M | North America | Follow-on | General Catalyst | Fierce Biotech |
| Sophont | Sep 2025 | Multimodal medical AI startup. | Clinical AI Tools | Seed | $9.22M | North America | First financing | None counted | PR Newswire |
| Penguin AI | Sep 2025 | AI digital workers and agents for healthcare administrative workflows. | Care Workflow AI | Series A | $29.7M | North America | Follow-on | None counted | Penguin AI |
| Teton.ai | Sep 2025 | Predictive AI for senior-care monitoring and workflow. | Care Workflow AI | Series A | $20M | Europe | Follow-on | None counted | Business Wire |
| Reveal HealthTech | Sep 2025 | AI transformation partner for healthcare and life-science companies, including clinical trial and workflow AI tools. | Life Science AI | Series A | $7.2M | Asia-Pacific | Follow-on | None counted | PR Newswire |
| Hello Patient | Sep 2025 | Conversational AI for patient communications and healthcare front door. | Care Workflow AI | Series A | $22.5M | North America | Follow-on | None counted | Business Wire |
| Eyebot | Aug 2025 | Doctor-verified automated vision-test kiosks using AI-enabled vision workflow. | Diagnostic AI Software | Series A | $20M | North America | Follow-on | General Catalyst | PR Newswire |
| Method AI | Aug 2025 | AI-enhanced visualization for surgical oncology procedures. | Diagnostic AI Software | Series A | $20M | North America | Follow-on | Unknown | Business Wire |
| Chai Discovery | Aug 2025 | AI molecular design and drug-discovery foundation models. | Life Science AI | Series A | $70M | North America | Follow-on | Unknown | Business Wire |
| C8 Health | Jul 2025 | AI-powered best-practices implementation platform for hospitals. | Clinical AI Tools | Series A | $12M | North America | Follow-on | None counted | PR Newswire |
| Ambience Healthcare | Jul 2025 | Ambient AI platform for documentation, coding, CDI, and clinical workflows. | Care Workflow AI | Series C | $243M | North America | Follow-on | Oak HC/FT; a16z; Kleiner Perkins | Ambience Healthcare |
| OpenEvidence | Jul 2025 | AI medical search and DeepConsult agent for physicians. | Clinical AI Tools | Series B | $210M | North America | Follow-on | GV; Kleiner Perkins; Sequoia; Coatue; Thrive | OpenEvidence |
| Imagene AI | Jul 2025 | Multimodal foundation models for precision medicine. | Diagnostic AI Software | Series B | $23M | North America | Follow-on | None counted | BioSpace |
| Abridge | Jun 2025 | AI-powered care intelligence and ambient documentation. | Care Workflow AI | Series D+ | $300M | North America | Follow-on | a16z; Khosla Ventures | Abridge |
| Nabla | Jun 2025 | Ambient AI clinical documentation software. | Care Workflow AI | Series C | $70M | Europe | Follow-on | None counted | STAT |
| Autonomize AI | Jun 2025 | Agentic AI platform for regulated healthcare and life-science workflows. | Care Workflow AI | Series A | $28M | North America | Follow-on | None counted | Business Wire |
| Tandem Health | Jun 2025 | AI clinician assistant and healthcare co-pilot. | Care Workflow AI | Series A | $50M | Europe | Follow-on | Unknown | Sifted |
| Clarium | May 2025 | AI-powered healthcare supply-chain resiliency platform. | Care Workflow AI | Series A | $27M | North America | Follow-on | General Catalyst | PR Newswire |
| Carta Healthcare | May 2025 | AI-powered clinical data abstraction and analytics. | Clinical AI Tools | Series B | $18.25M | North America | Follow-on | None counted | PR Newswire |
| Inductive Bio | May 2025 | AI models for small-molecule drug discovery. | Life Science AI | Series A | $25M | North America | Follow-on | a16z; Lux Capital | Inductive Bio |
| Plenful | Apr 2025 | AI workflow automation platform for healthcare operations. | Care Workflow AI | Series B | $50M | North America | Follow-on | Bessemer | PR Newswire |
| Blooming Health | Apr 2025 | AI-driven social-care engagement platform. | Care Workflow AI | Series A | $26M | North America | Follow-on | Insight Partners | PR Newswire |
| Ascertain | Apr 2025 | AI-powered care-team and care-journey automation. | Care Workflow AI | Series A | $10M | North America | Follow-on | None counted | PR Newswire |
| Heidi Health | Apr 2025 | AI scribe for clinicians. | Care Workflow AI | Series A | $16.6M | Asia-Pacific | Follow-on | None counted | Heidi Health |
| Isomorphic Labs | Mar 2025 | AI-first drug design and development platform spun out of Google DeepMind. | Life Science AI | Unknown | $600M | Europe | First financing | Thrive Capital; GV | Isomorphic Labs |
| Lila Sciences | Mar 2025 | Scientific superintelligence platform for life sciences using AI and autonomous labs. | Life Science AI | Seed | $200M | North America | First financing | None counted | Crunchbase |
| Biorce | Mar 2025 | AI clinical-trial technology. | Life Science AI | Series A | $52.5M | Europe | Follow-on | None counted | Clinical Trials Arena |
| Ataraxis AI | Mar 2025 | AI precision-medicine platform for breast cancer prognosis and prediction. | Diagnostic AI Software | Series A | $20.4M | North America | Follow-on | None counted | Business Wire |
| OpenEvidence | Feb 2025 | AI medical search and clinical decision support for verified clinicians. | Clinical AI Tools | Series A | $925M | North America | Follow-on | Sequoia Capital | Crunchbase |
| Abridge | Feb 2025 | AI clinical documentation and medical conversation intelligence platform. | Care Workflow AI | Series D+ | $250M | North America | Follow-on | IVP; Lightspeed; Bessemer | HIT Consultant |
| Anatomy Financial | Dec 2024 | AI-powered healthcare lockbox and payments automation. | Revenue Cycle AI | Series A | $19M | North America | Follow-on | Not disclosed in available source | Business Wire |
| Hyro | Dec 2024 | Responsible voice and chat AI agents for healthcare operations. | Care Workflow AI | Series B | $15M | North America | Follow-on | Healthier Capital; Macquarie | Hyro |
| Cradle | Nov 2024 | Generative AI protein engineering software for biopharma and synthetic biology. | Life Science AI | Series B | $73M | Europe | Follow-on | IVP; Index Ventures | TechCrunch |
| Enveda | Nov 2024 | AI-enabled discovery of medicines from natural chemistry. | Life Science AI | Series C | $130M | North America | Follow-on | Kinnevik; Baillie Gifford; Lux Capital | Fierce Biotech |
| Aignostics | Oct 2024 | Multimodal AI pathology platform for precision medicine and biopharma. | Diagnostic AI Software | Series B | $34M | Europe | Follow-on | Mayo Clinic; Boehringer Ingelheim Venture Fund; HTGF | Aignostics |
| Suki | Oct 2024 | AI assistant and ambient documentation platform for clinicians. | Care Workflow AI | Series D+ | $70M | North America | Follow-on | Hedosophia | Business Wire |
| Qure.ai | Sep 2024 | AI diagnostic imaging software and foundational healthcare AI models. | Diagnostic AI Software | Series D+ | $65M | Asia-Pacific | Follow-on | Lightspeed; Merck GHI; Novo Holdings | Qure.ai |
| Ferrum Health | Sep 2024 | Enterprise platform for deploying clinical AI in health systems. | Clinical AI Tools | Series A | $16M | North America | Follow-on | Foundry; UnitedHealthcare Accelerator | PRWeb |
| Caresyntax | Aug 2024 | AI-enabled precision surgery platform. | Clinical AI Tools | Series C | $80M | Europe | Follow-on | BlackRock Innovation Capital; Optum Ventures | Caresyntax |
| Thoughtful AI | Jul 2024 | AI agents for healthcare revenue cycle automation. | Revenue Cycle AI | Series A | $20M | North America | Follow-on | Drive Capital | HIT Consultant |
| Regard | Jul 2024 | AI clinical insights platform for EHR data. | Clinical AI Tools | Series B | $61M | North America | Follow-on | Oak HC/FT; Cedars-Sinai Health Ventures | PR Newswire |
| Formation Bio | Jun 2024 | AI-native drug development and clinical development platform. | Life Science AI | Series D+ | $372M | North America | Follow-on | a16z; Sanofi; Sequoia Heritage; Thrive | Fierce Biotech |
| Valar Labs | May 2024 | AI diagnostic tests predicting cancer therapy response. | Diagnostic AI Software | Series A | $22M | North America | Follow-on | DCVC; a16z Bio + Health | Business Wire |
| Atropos Health | May 2024 | Generative-AI real-world evidence automation for care and life sciences. | Life Science AI | Series B | $33M | North America | Follow-on | McKesson Ventures; Merck GHI; Mayo Clinic; CVS Health Ventures | Atropos Health |
| SmarterDx | May 2024 | Clinical AI for hospital revenue integrity and quality. | Revenue Cycle AI | Series B | $50M | North America | Follow-on | Transformation Capital; Bessemer | PR Newswire |
| Sift Healthcare | May 2024 | AI payment and revenue cycle intelligence. | Revenue Cycle AI | Series B | $20M | North America | Follow-on | B Capital | PR Newswire |
| Rad AI | May 2024 | Generative AI reporting and workflow tools for radiologists. | Care Workflow AI | Series B | $50M | North America | Follow-on | Khosla Ventures; Gradient Ventures | Rad AI |
| Alaffia Health | Apr 2024 | Generative AI for health plan claim operations. | Payer AI Platforms | Series A | $10M | North America | Follow-on | FirstMark | PR Newswire |
| Xaira Therapeutics | Apr 2024 | AI-enabled drug discovery and therapeutic development company. | Life Science AI | Series A | $1,000M | North America | First financing | ARCH; Foresite; NEA; Sequoia; Lightspeed; Lux | Fierce Biotech |
| Tennr | Mar 2024 | AI document and referral automation for healthcare practices. | Care Workflow AI | Series A | $18M | North America | Follow-on | a16z; Y Combinator | TechStartups |
| Hippocratic AI | Mar 2024 | Safety-focused healthcare LLM and clinical AI agent platform. | Clinical AI Tools | Series A | $53M | North America | Follow-on | General Catalyst; a16z | Universal Health Services |
| CodaMetrix | Mar 2024 | AI medical coding and revenue cycle automation. | Revenue Cycle AI | Series B | $40M | North America | Follow-on | Transformation Capital; SignalFire | CodaMetrix |
| Zephyr AI | Mar 2024 | AI precision medicine and oncology/cardiometabolic analytics. | Life Science AI | Series A | $111M | North America | Follow-on | Revolution Growth; Eli Lilly | Business Wire |
| Abridge | Feb 2024 | Generative AI clinical documentation and medical conversation intelligence. | Care Workflow AI | Series C | $150M | North America | Follow-on | Lightspeed; Redpoint; IVP; USV; Bessemer; NVIDIA | Abridge |
| Fabric | Feb 2024 | AI-powered care enablement and patient workflow platform. | Care Workflow AI | Series A | $60M | North America | Follow-on | General Catalyst; Thrive; GV | HIT Consultant |
| Ambience Healthcare | Feb 2024 | AI operating system and documentation and workflow automation for healthcare organizations. | Care Workflow AI | Series B | $70M | North America | Follow-on | Kleiner Perkins; OpenAI Startup Fund; a16z | PR Newswire |
| AQEMIA | Jan 2024 | Generative-AI and physics-based drug discovery platform. | Life Science AI | Series A | $32.4M | Europe | Follow-on | Eurazeo; Bpifrance | Business Wire |
| Forta | Jan 2024 | AI-enabled healthcare delivery platform focused on access to dependable care. | Clinical AI Tools | Series A | $55M | North America | Follow-on | Insight Partners | PR Newswire |
| Nabla | Jan 2024 | AI copilot and ambient documentation assistant for doctors. | Care Workflow AI | Series B | $24M | Europe | Follow-on | Cathay Innovation | TechCrunch |
INSIGHTS
The insights below come from reviewing disclosed equity rounds raised by pure-play Healthcare AI companies across 2024, 2025, and year-to-date 2026, with particular attention to the shift in funding patterns through May 2026.
- The Healthcare AI market has not weakened simply because 2026 capital is lower than the comparable 2025 period. The stronger signal is that deal count is much higher, which means the market is broadening while the mega-round distortion is fading.
- The 2025 Healthcare AI market was a capital spike, not a normal baseline. Any 2026 comparison that treats early 2025 as ordinary will overstate the degree of current-year slowdown.
- Median round size is more useful than average round size for understanding the typical Healthcare AI company. Averages are pulled upward by very large rounds, while the median better captures the financing environment most companies actually face.
- The Healthcare AI market is evolving from “who can raise the biggest AI platform round?” to “who can prove ownership of a painful healthcare workflow?” That shift favors companies with measurable ROI, distribution, clinical trust, regulatory credibility, or payer economics.
- Care Workflow AI is the broadest category but not the most capital-intensive category. That usually indicates a crowded commercial application layer rather than a single winner-takes-all infrastructure layer.
- Clinical AI Tools have stronger winner-takes-more characteristics than broad workflow automation. Once physicians trust a clinical answer layer, repeated usage, evidence grounding, and brand credibility can compound faster than in narrow administrative workflows.
- Revenue Cycle AI’s return as a visible standalone category in 2026 matters because RCM has one of the clearest budget owners in healthcare. Investors are likely rewarding the fact that financial impact is easier to measure than broad care-quality improvement.
- Payer AI is still underdeveloped relative to the size of payer budgets. The rise from one small 2024 deal to three 2026 deals suggests investors are beginning to recognize payer workflows as a more explicit AI category.
- Diagnostic AI looks quiet by deal count but powerful by proof threshold. Few diagnostic AI companies raise, but those that pass clinical, regulatory, and deployment gates can still command large later-stage rounds.
- Life Science AI has moved from spectacular platform-creation financings to more normalized activity. That does not imply category failure; it implies that Xaira, Isomorphic Labs, Lila Sciences, and similar rounds were exceptional events rather than repeatable annual patterns.
- First financings are no longer setting the tone. The Healthcare AI market is increasingly dominated by follow-ons, which means investors are using observed progress rather than pure formation narratives to allocate the largest checks.
- The decline in first-financing capital share is a maturity signal. New startups can still enter, but they are not receiving the same oversized launch-round treatment as Xaira, Isomorphic Labs, or Lila Sciences.
- North America’s dominance is not just a venture-capital artifact. The U.S. healthcare system creates unusually large AI opportunities because administrative complexity, payer fragmentation, physician burden, and health-system financial stress are all acute and monetizable.
- Europe’s 2026 slowdown should be read as a lack of mega-round recurrence, not as a collapse in company quality. Europe’s 2025 capital share was unusually dependent on very large life-science financing events.
- Asia-Pacific’s signal remains company-specific rather than ecosystem-wide. Heidi Health shows that APAC companies can break through, but the region has not yet produced broad deal volume comparable to North America.
- The Middle East’s 2026 capital share is driven by Aidoc rather than by a broad regional funding base. One globally relevant clinical AI company should not be mistaken for a regional market surge.
- The Healthcare AI market is becoming more selective about what counts as defensible. Generic AI agents are less compelling than AI systems embedded in regulated workflows, proprietary data loops, payment flows, or clinical decision boundaries.
- Investor attention is shifting toward “AI with a budget owner.” Claims review, RCM, medication access, documentation, diagnostic triage, and clinical search all have clearer economic buyers than abstract quality-improvement tools.
- The best-funded companies increasingly present themselves as platforms or operating systems, not point solutions. That language matters because investors are underwriting expansion across multiple workflows, not just one automation use case.
- The Healthcare AI market is not one market in practice. It is at least six markets with different proof requirements: clinical trust, diagnostic validation, workflow ROI, revenue impact, payer savings, and life-science discovery leverage.
- The same round size means different things by category. A $30M Care Workflow AI round can be strong, while a $30M Life Science AI round may look modest if the company claims platform-scale drug-discovery ambition.
- The next phase of the Healthcare AI market will separate adoption theater from durable value. Companies with pilots but no workflow ownership will struggle, while companies with embedded usage, measurable ROI, clinical validation, or proprietary feedback loops will keep attracting capital.
This chart, featured in our healthcare AI market deck, shows how symptom checker app technology has evolved over time
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this Healthcare AI funding tracker by reviewing publicly disclosed equity rounds raised by pure-play Healthcare AI companies between January 2024 and May 2026. A company counts as pure-play when more than 80% of its activity is dedicated to healthcare-specific AI software, AI models, AI-enabled clinical tools, diagnostic AI software, care workflow AI, revenue-cycle AI, payer AI platforms, or life-science AI.
We applied four core filters to build the dataset. First, we only included equity rounds, so grants, debt, structured financings, SPAC transactions, acquisitions, and business combinations are excluded unless the disclosed equity portion could be separated and counted. Second, we only counted disclosed rounds of $300K or more. Third, we only kept pure-play Healthcare AI companies, which means we excluded general AI infrastructure, horizontal enterprise AI, consumer wellness, fitness, non-AI healthcare services, and companies where AI was only an incidental feature. Fourth, every entry had to be confirmed by a direct company announcement, a press release, tier-1 media, a specialized healthcare or life-science source, or a relevant regional publication.
Undisclosed-amount rounds are excluded because including them would distort dollar-based metrics such as average round size, category capital share, and concentration ratios. Mixed financings were handled conservatively: when an announcement combined equity with debt or other facilities, only the disclosed equity portion was counted when separable.
The final tracker reflects a public-source dataset, not a private financing database. Privately raised rounds, unannounced rounds, poorly indexed small financings, and transactions without a disclosed amount are necessarily missing, which is a known limitation of any public-only market tracker. Every average, median, share, stage split, geography split, investor count, and concentration ratio is computed on the qualifying disclosed sample.
Related blog posts
- What is the latest update in healthcare AI?
- What is the latest news in healthcare AI?
- What is the real size of the healthcare AI market?
- What is the latest funding news in healthcare AI?
- How funding activity has changed in healthcare AI
- Which startups have raised the most funding in the healthcare AI market?
- Which startups are the most valued in the healthcare AI market?
